Nucleome Looks To Decode The ‘Dark Genome’ With New Technology
Insights From CEO Danuta Jeziorska
Executive Summary
Despite accounting for 98% of our DNA, the ‘dark genome’ has yet to be effectively harnessed for drug discovery. Nucleome Therapeutics’ new modeling technology could finally provide the tools that have been missing, says CEO Danuta Jeziorska.
You may also be interested in...
Biotech Foundations: Networks And Lab Space Are As Crucial As Funding
BioInnovation Institute chief business officer Bobby Soni shares how the life sciences incubator sources entrepreneurs and science globally, and the range of tools it provides to translate this into commercially viable companies.
Lithuania Caps Off Decade Of Growth With Stellar 2020
Lithuania’s life sciences sector has harnessed the country’s talent, infrastructure and government support to realize a decade of unprecedented growth. With the industry now maturing, can the Baltic state overcome challenges to become a significant European player?
Execs On The Move, September 2021
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.